InvOpps GP IV, L.L.C. 4
4 · Oyster Point Pharma, Inc. · Filed May 21, 2020
Insider Transaction Report
Form 4
InvOpps GP IV, L.L.C.
Director10% Owner
Transactions
- Purchase
Common Stock, par value $0.001 per share
2020-05-19$28.00/sh+119,393$3,343,004→ 1,850,818 total(indirect: See Footnotes) - Purchase
Common Stock, par value $0.001 per share
2020-05-19$28.00/sh+59,178$1,656,984→ 917,768 total(indirect: See Footnotes)
Footnotes (4)
- [F1]Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US").
- [F2]Reflects securities directly held by InvOpps IV, L.P. ("Invus IV").
- [F3]InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
- [F4]Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.